Investors

Nov 15, 2011

TSX Exchange Symbol: RVX

CALGARY, Nov. 15, 2011 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that a patent covering RVX-208 has been issued by the United States Patent and Trademark Office, adding to the portfolio of patents held by Resverlogix.

Patent US 8,053,440 contains composition of matter claims to the Company's clinical lead molecule, RVX-208, and structurally related compounds. Other claims related to RVX-208 are being pursued in other applications.  In addition, Resverlogix has received notices of allowance in other cases and are attending to formalities before these patents issue.  Corresponding applications in other jurisdictions are still pending.

"We are extremely pleased with the issuing of one of the key patents covering RVX-208. It further solidifies Resverlogix as a key player in the cardiovascular disease market and provides exclusive coverage for RVX-208 until 2030," stated Donald McCaffrey, President & Chief Executive Officer of Resverlogix.

Mr. McCaffrey continued, "Resverlogix devotes significant resources to ensure the protection of ideas and inventions related to the core areas of our business. Today, the Company's intellectual property portfolio covers compositions, methods and treatments for cardiovascular and inflammatory diseases, cancers and fibrotic diseases.  We believe that our know-how in these disease states will provide a significant competitive advantage. Resverlogix intends to continue to develop and protect our proprietary tools, methods, and trade secrets."

The Resverlogix patent portfolio currently consists of four issued patents:

1. Compounds for the prevention and treatment of cardiovascular disease, US 8,053,440.
2. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases, US 7,846,915.
3. Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices, NZ 566180.
4. Compounds and methods for down regulating the effects of TGF-beta, EP 1 648 520 B1.

It is the policy of Resverlogix to require employees, consultants, members of our Scientific and Clinical Advisory Boards, and other third parties in collaborative agreements to execute confidentiality agreements. Employee, consultant and contract research organization agreements specify that all inventions resulting from work performed using the Company's resources and work completed during employment/services performed are the Company's exclusive property, to the extent permitted by law.

About RVX-208

RVX-208 is a novel small molecule that stimulates endogenous ApoA-I production to trigger the synthesis of HDL. The use of this approach will enhance the functionality of HDL. ApoA-I is the major protein component of HDL.  The main role of these particles is to act as the body's natural defense system against atherosclerosis by mediating a normal physiologic process called reverse cholesterol transport (RCT).  This pathway enables cholesterol, including that within atherosclerotic plaques of vessel walls, to be transported to the liver for further processing and elimination from the body.  Enhanced RCT clearance of cholesterol from vessel walls should reduce or prevent atherosclerosis. The ability of RVX-208 to increase ApoA-I production and thereby augment RCT differentiates it from other HDL therapies. RVX-208 is positioned to be one of the most promising drugs in development for the treatment of atherosclerosis.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas Plaque Regression program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I production. These vital therapies are focused to address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Alzheimer's disease, Peripheral Artery Disease and Autoimmune diseases. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions.  Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional assumptions and risk factors discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contacts: